Eli Lilly received FDA approval for Onswik on September 24, 2026. This once-weekly basal insulin treats adults with type 2 diabetes. The medication reduces the number of required injections by over 300 per year. Positive results from the QWINT Phase 3 clinical trials supported the regulatory decision.
The company also broke ground on a $6.5 billion manufacturing facility in Houston, Texas. This site serves a broader strategy to expand domestic production capabilities.
Lilly entered a strategic research collaboration with InnoCare Pharma valued at up to $3.35 billion. The partnership targets the development of five new medicines for critical unmet medical needs.